"rationale","instanceType","description","label","name","uuid:ID","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","The main design for the study","","Study Design 1","912e4f29-1b68-4d36-bc28-34887b947bd9","StudyDesign_1"
